Gemcitabine-oxaliplatin (GEMOX)‎ for epithelial ovarian cancer patients resistant to platinum-based chemotherapy

Abstract EN

Background : Patients with platinum-resistant epithelial ovarian cancer (EOC) experience poor outcome.

Currently, no clearly superior management strategy exists for platinumresistant EOC patients.

Purpose : Analyze the efficacy and safety of gemcitabine–oxaliplatin (GEMOX) in platinum resistant EOC patients.

Patients and methods : Thirty-two patients with platinum-based resistant EOC were included.

Studied patients had received GEM at the dose of 1000 mg/m2 on days 1 and 8 and OX 100 mg/m2 on day 1, administered over 2 h 30 min after GEM infusion of 3 week treatment cycle.

Results: In the evaluation of tumor response, none of patients had achieved CR while PR, SD, were observed in 7 (21.9 %), 9 (28.1%) respectively, clinical benefit (CR+ PR +SD) was recorded in 50 % of patients while PD was observed in 16 (50 %) patients.

In regard to survival, the median value of OS was 10.5 months (range, 2.2–17.5 months).

The median value of PFS was 6.37 months (range, 1–17.5 months).

The one-year OS rate was 34.4% and the one-year PFS rate was 12.5 %.

Concerning hematological toxicity grade 3 neutropenia was recorded in 4 (12.5 %) patients while grade 4 febrile neutropenia was recorded in 2 (6.3 %) patients and grade 4 anemia was represented by 3.1%.

Grade 1–2 fatigue was the most common non-hematological toxicity and represented by 65.6 % of patients.

Grade 3 non hematological toxicity was recorded with nausea/vomiting and hepatic toxicity represented by 3.1 % for both.